Company Overview of Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
142 Temple Street
New Haven, CT 06510
Founded in 2003
Key Executives for Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Seroyal USA, Inc.||United States|
|Elanco Animal Health, Inc.||United States|
|HealthAsure, Inc.||United States|
|Fitzgerald Industries International, Inc.||United States|
|GeneraMedix, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Marinus Pharmaceuticals, Inc., please visit www.marinuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.